infect
avian
influenza
induc
reactiv
oxygen
speci
accumul
caus
hyperimmun
respons
viru
may
advers
effect
vital
organ
result
high
pathogen
mortalityclin
care
acut
respiratori
distress
syndrom
may
result
ischemia
reperfus
injuri
alveolar
cell
poorli
ventil
poorli
suppli
blood
main
mechan
includ
mitochondri
permeabl
transit
releas
apoptot
mediatorscombin
immunomodul
antivir
agent
significantli
reduc
mortal
mice
infect
avian
influenza
viru
aiv
howev
reduc
mortal
rate
still
rel
high
viru
neuraminidas
digest
lysosom
membran
glycoprotein
induc
lysosom
lysi
releas
lysosom
proteas
anoth
mechan
aivinduc
cell
death
new
treatment
new
drug
avian
influenza
develop
continu
still
high
mortal
rate
acut
respiratori
distress
syndrom
clinic
care
enabl
surviv
partial
aivinfect
patient
wherea
other
die
immunomodul
antivir
agent
complet
cure
aiv
infect
hope
reduc
mortal
rate
case
ordinari
influenza
last
decad
endless
stream
sever
acut
respiratori
syndrom
sar
influenza
associ
malign
respiratori
diseas
emerg
threaten
human
health
serious
high
mortal
rate
infecti
natur
diseas
usual
caus
psycholog
panic
among
public
seriou
diseas
report
may
patient
studi
admit
intens
care
unit
new
treatment
new
drug
avian
influenza
develop
continu
high
mortal
rate
introspect
current
therapi
avian
influenza
develop
better
one
review
therapeut
use
drug
avian
influenza
associ
pneumonia
summar
gener
convent
therapi
use
antivir
drug
result
mortal
rate
wherea
new
therapi
antivir
drug
immunomodul
reduc
mortal
rate
howev
still
high
ratio
main
reason
may
cell
death
pathway
induc
aiv
block
therapi
figur
end
review
larg
reagent
combin
propos
may
greatli
reduc
mortal
rate
prospect
symptom
infect
upper
respiratori
tract
infect
heavi
mild
cough
attach
attent
major
patient
howev
diseas
progress
quickli
ten
day
post
infect
pulmonari
symptom
appear
immedi
pneumophila
next
condit
involv
prolifer
lung
seriou
lung
exud
low
pulmonari
oxygen
low
oxygen
blood
patient
without
effect
treatment
time
develop
acut
respiratori
distress
syndrom
ard
may
die
day
symptom
type
avian
influenza
sar
almost
henc
key
surviv
patient
may
suppress
viru
also
control
inflammatori
respons
host
sar
mortal
statist
publish
world
health
organ
show
overal
averag
mortal
rate
mortal
rate
young
peopl
strong
immun
much
higher
old
peopl
weak
overal
mortal
rate
howev
youth
group
year
old
individu
got
highest
mortal
rate
mortal
rate
peopl
year
moreov
death
mostli
occur
middleag
adult
sever
case
far
higher
year
age
group
contrari
season
influenza
fatal
diseas
occur
often
elderli
peopl
year
old
overal
mortal
rate
research
believ
infect
avian
influenza
caus
multipl
complic
patient
result
multiorgan
failur
may
relat
hyperimmun
respons
viru
may
advers
effect
vital
organ
result
high
pathogen
viru
may
set
cytokin
storm
exampl
interferon
ifn
induc
protein
chemokin
cytokin
outbreak
like
lead
cell
data
may
suggest
healthi
young
peopl
would
becom
main
target
attack
word
stronger
immun
system
sever
inflammatori
respons
infect
thu
higher
risk
death
aiv
kill
us
may
kill
newborn
viru
fullscal
statist
avail
nevertheless
high
mortal
rate
rapid
diseas
similar
cytokin
burst
excess
immun
respons
expect
cytokin
burst
patient
prove
recent
reactiv
oxygen
speci
ro
crucial
role
inflammatori
aggreg
neutrophil
pulmonari
alveoli
activ
releas
oxygenfre
radic
proteas
lipid
peroxid
result
injuri
pulmonari
microvascular
membran
alveolar
epitheli
membran
subsequ
pulmonari
edema
ard
activ
neutrophil
gener
ro
exponenti
time
rate
rest
cell
oxid
injuri
includ
follow
lipid
peroxid
detriment
structur
function
cell
membran
organel
membran
ii
enzym
inactiv
iii
inactiv
proteas
inhibitor
releas
lysosom
proteas
iv
work
blood
plasma
induc
strong
chemoattract
caus
neutrophil
aggreg
ro
product
subsequ
sever
lung
thu
ro
form
posit
feedback
loop
could
selfamplifi
among
ro
scaveng
ascorb
acid
vitamin
c
vc
best
choic
effect
nontox
easi
absorb
stabl
other
similar
reduc
glutathion
vc
scaveng
ro
nonenzymat
ninteenth
centuri
vc
use
treat
hepat
enceph
influenza
sar
viral
nobel
laureat
chemist
linu
paul
publish
book
vitamin
c
common
cold
wherein
advoc
high
dose
vc
prevent
treat
littl
direct
evid
show
high
amount
vc
would
help
patient
sever
avian
influenza
infect
howev
investig
show
sever
public
locat
includ
vietnam
mani
human
infect
avian
flu
suggest
surviv
may
occur
particular
viral
load
constitut
moder
infect
may
small
enough
vc
accident
acquir
diet
adequ
defend
speci
normal
mammal
synthes
vc
averag
mgkg
bodi
weight
daili
gday
normal
kg
human
amount
found
essenti
optimum
health
resist
mani
summari
larg
number
know
effect
inhibit
viral
replic
appar
symptom
allevi
usual
requir
mm
vc
g
l
human
blood
howev
gener
oral
dosag
vc
tablet
mg
daili
much
lower
dose
requir
influenza
treatment
higher
absorpt
effici
consid
g
vc
oral
administr
may
caus
diarrhea
nausea
vomit
stomach
cramp
side
inject
approach
could
adopt
patient
infect
avian
influenza
addit
longterm
use
highdos
vc
gday
caus
scurvi
abrupt
stop
thu
vc
inject
reduc
gradual
recoveri
stop
patient
identifi
infect
aiv
sick
coupl
day
pulmonari
symptom
start
develop
alveolar
cell
may
alreadi
damag
therefor
risk
develop
acut
respiratori
failur
high
time
pretreat
vc
diagnosi
hospit
may
import
patient
avoid
lethal
simpli
provid
human
mgkgbodi
weight
vc
one
dose
oral
fix
schedul
replic
suffici
seen
normal
mammal
mice
bird
synthes
consider
amount
still
infect
avian
influenza
therefor
addit
treatment
ro
scaveng
appli
avianinfluenzainfect
patient
pneumonia
continu
increas
alveolarcapillari
membran
permeabl
common
mitochondria
critic
role
mediat
calcium
overload
oxid
damag
eg
hydrogen
peroxid
induc
cell
death
ischemia
reperfus
ir
mitochondri
permeabl
transit
mpt
injuri
lead
mitochondri
swell
outer
membran
ruptur
releas
apoptot
mediat
cytochrom
c
mpt
pore
thought
consist
adenin
nucleotid
transloc
voltagedepend
anion
channel
cyclophilin
cyclosporin
csa
effect
inhibit
cyclophilin
therefor
protect
myocardi
cell
form
ir
injuri
myocardi
infarct
infect
inactiv
cellular
catalas
thu
lead
accumul
ro
mainli
hydrogen
peroxid
wherea
induc
extracellular
calcium
influx
lead
ro
accumul
extracellular
calcium
influx
accompani
mitochondri
damag
also
found
hypoxemia
patient
lung
thu
ro
accumul
especi
hydrogen
peroxid
calcium
influx
may
common
injuri
factor
ir
injuri
ard
damag
csa
may
protect
effect
damag
caus
avian
influenza
infect
clinic
care
ard
may
result
ir
injuri
alveolar
cell
poorli
ventil
poorli
suppli
blood
avianinfluenzainfect
patient
often
develop
hypox
pulmonari
vasoconstrict
hpv
essenti
physiolog
mechan
lung
direct
blood
perfus
poorli
ventil
wellventil
lung
area
optim
ga
exchang
hpv
develop
may
caus
mismatch
blood
flow
alveolar
ventil
may
result
lifethreaten
ard
clinic
care
usual
carri
time
exampl
mechan
ventil
highflow
oxygen
therapi
corticosteroid
treatment
inhal
nitric
oxid
howev
treatment
may
restor
blood
oxygen
suppli
poorli
ventil
poorli
suppli
alveolar
cell
damag
similar
ir
injuri
may
occur
upon
hpv
mechan
ventil
highflow
oxygen
therapi
may
restor
oxygen
suppli
poorli
ventil
alveolar
cell
case
mismatch
blood
flow
alveolar
ventil
corticosteroid
treatment
inhal
nitric
oxid
administr
may
restor
blood
suppli
poorli
suppli
wellventil
alveolar
cell
condit
ir
injuri
similar
damag
may
occur
figur
word
sever
cell
death
may
happen
ard
clinic
manag
time
occurr
hpv
hypoxemia
csa
effect
inhibit
kind
damag
therefor
may
key
drug
surviv
ard
patient
nevertheless
csatreat
cell
protect
bax
bcell
lymphoma
associ
x
protein
tumor
necrosi
induc
mitochondri
dysfunct
cell
although
virus
dramat
induc
factor
alveolar
tnf
activ
apoptot
pathway
ie
tradd
rip
jnk
surviv
pathway
mediat
transcript
surviv
gene
ro
accumul
trigger
signal
facilit
apoptot
balanc
proapoptot
factor
bax
antiapoptot
member
famili
regul
cellular
redox
statu
tilt
favor
superoxid
abet
cell
surviv
prolifer
contrari
tilt
toward
hydrogen
peroxid
gener
intracellular
milieu
permiss
death
therebi
high
dose
vc
antioxid
mainli
scaveng
hydrogen
peroxid
may
block
tnf
baxinduc
apoptosi
figur
rapamycin
regul
level
may
exacerb
autophagi
may
lead
sever
cell
thu
rapamycin
may
suitabl
treatment
aiv
infect
csa
also
inhibit
calcineurin
calcineurin
key
enzym
tcell
activ
stimul
transcript
nfat
tcellspecif
transcript
factor
promot
element
thu
csa
block
activ
cell
suppress
gener
varieti
cytokin
csa
could
replac
csa
work
immunosuppress
similar
also
protect
maintain
integr
mitochondri
nevertheless
mani
side
effect
found
csa
exampl
renal
tubular
toxic
lesion
thu
substitut
smallmolecul
chemic
compound
develop
recent
howev
none
use
clinic
far
csa
show
appar
side
effect
longterm
use
usual
year
henc
current
aiv
therapi
usual
within
month
csa
could
use
expedi
szretter
et
show
pretreat
significantli
reduc
replic
viru
zheng
et
indic
combin
immunomodul
antivir
agent
significantli
reduc
mortal
mice
infect
high
inoculum
influenza
viru
use
two
immunomodul
celecoxib
inhibitor
mesalazin
salicyl
acid
two
drug
caus
signific
immunosuppress
henc
hardli
influenc
bodi
immun
system
six
eight
cytokin
induc
macrophag
inflammatori
protein
regul
activ
normal
cell
express
secret
monocyt
chemotact
protein
suppress
celecoxib
mesalazin
therefor
celecoxib
mesalazin
may
two
good
candid
drug
could
suppress
cytokin
storm
besid
csa
peopl
may
argu
csa
typic
immunosuppress
agent
may
weaken
bodi
resist
aiv
howev
consid
avian
influenza
caus
excess
immun
respons
could
specul
appropri
regul
immun
hamper
bodi
normal
resist
aiv
fact
csa
affect
influenza
viru
protein
inhibit
nuclear
export
viral
mrna
subsequ
inhibit
viru
previou
studi
report
acut
lung
injuri
caus
chemic
microbi
insult
secondari
gener
hostderiv
oxid
phospholipid
could
potent
stimul
tolllik
receptor
depend
recent
studi
shown
antagonist
eritoran
protect
mice
lethal
influenza
eritoran
altern
immunomodul
besid
csa
celecoxib
mesalazin
mention
control
influenzaassoci
inflamm
figur
eritoran
origin
design
drug
septicemia
recent
report
show
surviv
rate
mouseadapt
influenza
infect
mice
could
reach
eritoran
treatment
mice
administ
day
influenza
infect
indic
strong
immunomodulatori
properti
may
stronger
immunomodul
howev
eritoran
use
formal
clinic
far
observ
may
caus
notabl
side
effect
dosedepend
incid
similar
csa
also
central
role
ir
might
suggest
similar
aivinduc
inflammatori
reaction
irmedi
immun
respons
neutrophil
lysosom
contain
varieti
neutral
proteas
acid
proteas
neutrophil
activ
destroy
lysosom
lysi
occur
proteas
releas
caus
surround
protein
degrad
increas
alveolarcapillari
membran
thu
elastas
inhibitor
consid
aiv
infect
treatment
howev
sivelestat
expens
broadspectrum
proteas
inhibitor
ulinastatin
also
inhibit
neutrophil
elastas
lysosom
lysi
may
use
altern
cell
viru
neuraminidas
na
digest
lysosom
membran
glycoprotein
affect
lysosom
hydrolas
therebi
undermin
integr
treatment
proteas
inhibitor
ulinastatin
could
inhibit
destruct
process
could
therefor
potenti
import
ard
prevent
cure
figur
aiv
infect
cure
suppress
viral
replic
assembl
adopt
time
na
inhibitor
oseltamivir
relenza
call
zanamivir
usual
first
choic
aiv
besid
two
licens
ionchannel
inhibitor
amantadin
rimantadin
also
anoth
na
inhibitor
peramivir
biocryst
pharmaceut
durham
nc
usa
phase
trial
intraven
intramuscular
rout
anoth
longact
na
inhibitor
design
studi
use
inhal
viral
polymeras
inhibitor
favipiravir
activ
three
type
influenza
viru
b
c
also
activ
rna
virus
includ
hemorrhag
fever
sialidas
fusion
protein
inhibitor
fludas
fusion
construct
incorpor
sialidas
actinomyc
viscosu
common
oral
bacterium
link
humanepitheliumanchor
domain
mass
produc
escherichia
sialidas
target
viral
attach
process
earli
event
replic
influenza
viral
hemagglutinin
inhibitor
cyanovirinn
thiazolid
also
test
new
antiinfluenza
drug
develop
recent
mechanismbas
coval
na
geldanamycin
inhibitor
viral
polymeras
assembl
chaperon
moreov
combin
therapi
current
avail
antivir
support
data
anim
model
clinic
studi
combin
may
reduc
risk
develop
resist
influenza
viru
allevi
ard
mechan
ventil
highflow
oxygen
therapi
inhal
nitric
oxid
administr
corticosteroid
inject
although
shortterm
highdos
glucocorticoid
may
caus
necrosi
femor
head
convent
approach
also
usual
appli
critic
variou
strategi
use
ard
care
extens
review
aiv
mutat
vari
rapidli
new
virus
emerg
constantli
possibl
made
combin
avian
influenza
aiv
antivir
resist
mutat
specimen
patient
infect
report
thu
vaccin
develop
alway
one
step
behind
therefor
pay
attent
respons
human
bodi
rather
charact
viru
excess
inflammatori
respons
restrain
aiv
may
clear
later
bodi
immun
mechan
case
ordinari
influenza
review
five
categori
drug
therapeut
strategi
aiv
infect
summar
antioxid
highdos
vc
ii
mitochondri
permeabl
protect
immunomodul
csa
without
celecoxibmesalazin
eritoran
iii
proteas
inhibitor
ulinastatin
iv
antivir
drug
oseltamivirrelenza
v
clinic
manag
ard
among
licens
drug
list
tabl
high
dose
vc
use
influenza
treatment
long
time
csa
also
use
treat
nonorgantransplantationassoci
pneumonia
celecoxib
mesalazin
two
prescript
drug
success
cure
mice
infect
ulinastatin
good
cur
effect
acut
lung
consid
work
differ
cell
death
pathway
four
categori
drug
might
ideal
use
larg
combin
reduc
mortal
rate
therapeut
combin
could
name
avian
influenza
cocktail
therapi
aict
similar
cocktail
therapi
howev
aict
may
addit
possibl
antagonist
effect
viru
replic
induct
cytokin
storm
moreov
possibl
side
effect
new
combin
therapi
test
yet
although
treatment
session
long
usual
week
moreov
dosag
singl
compound
adjust
accord
combin
exampl
blood
concentr
csa
vari
larg
among
individu
patient
may
dramat
influenc
therefor
care
pharmaceut
studi
conduct
aict
made
realli
enter
clinic
trial
human
aiv
infect
aict
individu
drug
may
also
effect
highmort
respiratori
viral
infect
besid
avian
influenza
might
modifi
use
diseas
therapi
sar
neonat
respiratori
distress
syndrom
organ
transplantationassoci
viral
pneumonia
